FDA Approves Sub-q Tx for jPIA – Kevzara
……….catching up on FDA approvals We usually don’t report on expanded indications for a therapy previously approved by the FDA. This time one such approval
September 6, 2024
……….catching up on FDA approvals We usually don’t report on expanded indications for a therapy previously approved by the FDA. This time one such approval
We’ve written about Value-Based Contracting (VBC) numerous times. The logic of VBC is self-evident. However, the feasibility and implementation of VBC is a totally different
The FDA recently approved a new infused therapy, Rytelo (imetelstat) from Geron Corporation, for the treatment of adult patients with low – to intermediate-1 risk
In the third century BCE a wonder of the world, the Colossus of Rhodes, stood as testament to ever lasting power and strength. As history tells,
………….. catching up on FDA Approvals The FDA recently approved a biosimilar….. meh news…… huh? But wait….. on the same day the FDA approved two biosimilars….. big news?
…….. catching up on FDA approvals The FDA recently approved a new infused therapy, Imdelltra (tarlatamab-dlle) from Amgen, indicated for the treatment of adult patients
The FDA recently approved a trastuzumab biosimilar, Hercessi (trastuzumab-strf; HLX02) from Accord BioPharma, to reference product Herceptin, for the treatment of several forms of HER2-positive
We just ran across an interesting article that spotlights four key takeaways from the Asembia Specialty Pharmacy Summit held earlier this year. Well, the article
Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the early press releases
The FDA recently approved an ORAL Tx, Xolremdi (mavorixafor) from X4 Pharmaceuticals, indicated in patients 12 years of age and older with WHIM (warts,hypogammaglobulinemia, infections
